NASDAQ
EFTRW

eFFECTOR Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

eFFECTOR Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.1
Today's High:
$0.1198
Open Price:
$0.1119
52W Low:
$0.0358
52W High:
$0.31
Prev. Close:
$0.11
Volume:
21397

Company Statistics

Market Cap.:
$0
Book Value:
-9.522
Revenue TTM:
$1.31 million
Operating Margin TTM:
-1809.48%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
0%
Return on Equity TTM:
0%

Company Profile

eFFECTOR Therapeutics Inc had its IPO on 2021-03-01 under the ticker symbol EFTRW.

The company operates in the Healthcare sector and Biotechnology industry. eFFECTOR Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of eFFECTOR Therapeutics Inc opened at $0.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.1 - $0.12, and closed at $0.1.

This is a -9.09% slip from the previous day's closing price.

A total volume of 21,397 shares were traded at the close of the day’s session.

In the last one week, shares of eFFECTOR Therapeutics Inc have slipped by -44.44%.

eFFECTOR Therapeutics Inc's Key Ratios

eFFECTOR Therapeutics Inc has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months eFFECTOR Therapeutics Inc’s revenue was $1.31 million with a gross profit of $0 and an EBITDA of $-23582000. The EBITDA ratio measures eFFECTOR Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, eFFECTOR Therapeutics Inc’s operating margin was -1809.48% while its return on assets stood at 0% with a return of equity of 0%.

In Q1, eFFECTOR Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.4%.

eFFECTOR Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.905 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into eFFECTOR Therapeutics Inc’s profitability.

eFFECTOR Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

eFFECTOR Therapeutics Inc stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$21.93 million
Total Liabilities
$26.65 million
Operating Cash Flow
$0
Capital Expenditure
$13000
Dividend Payout Ratio
0%

eFFECTOR Therapeutics Inc ended 2024 with $21.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.93 million while shareholder equity stood at $-4813000.00.

eFFECTOR Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $26.65 million in other current liabilities, 4000.00 in common stock, $-153580000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.31 million and cash and short-term investments were $19.01 million. The company’s total short-term debt was $20,303,000 while long-term debt stood at $0.

eFFECTOR Therapeutics Inc’s total current assets stands at $20.89 million while long-term investments were $0 and short-term investments were $8.70 million. Its net receivables were $0 compared to accounts payable of $3.79 million and inventory worth $0.

In 2024, eFFECTOR Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $13000.

Comparatively, eFFECTOR Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.1
52-Week High
$0.31
52-Week Low
$0.0358
Analyst Target Price
$

eFFECTOR Therapeutics Inc stock is currently trading at $0.1 per share. It touched a 52-week high of $0.31 and a 52-week low of $0.31. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.16 and 200-day moving average was $0.16 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About eFFECTOR Therapeutics Inc

The stock symbol (also called stock or share ticker) of eFFECTOR Therapeutics Inc is EFTRW

The IPO of eFFECTOR Therapeutics Inc took place on 2021-03-01

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Coforge Limited (COFORGE)
$5459.5
-56.2
-1.02%
$85.21
-6.69
-7.28%
$1587.85
-42.1
-2.58%
Jtekt India Limited (JTEKTINDIA)
$137.05
-9.05
-6.19%
$7.81
0
0%
$20.25
0.22
+1.1%
$0.2
0.06
+44.75%
PG FOILS LTD. (PGFOILQ)
$225.7
-10.45
-4.43%
$24.5
0.67
+2.81%
$26.98
-0.01
-0.04%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.

Address

11120 Roselle Street, San Diego, CA, United States, 92121